Promise and Progress - Science, Philanthropy and Industry
Issue No. 1
Science, Philanthropy and Industry
Date: July 16, 2014
The Model for 21st Century Cancer Medicine
From the Director
Science, Philanthropy and Industry: The Model for 21st Century Cancer Medicine
It has been fascinating to see how cancer genetics, epigenetics, and immunology conspire to support cancer development. This new understanding has been revealed because of the depth of expertise Kimmel Cancer Center investigators have as longstanding leaders in each of these fields.
I can remember a time when these now-heralded disciplines were scrutinized, particularly epigenetics. Although many researchers discounted its value, our team of talented scientists and clinicians—supported by a university system that reveres ingenuity and inventiveness—proved its validity. Our scientists overcame significant obstacles to make the connections and reveal a complex interplay that no one anticipated but that is vitally important to how cancer cells behave.
This collaborative research, unmatched at any other institution, has now resulted in some of the most promising clinical advances in recent years.
This success is an example of a unique partnership of science, industry, and philanthropy. At a time when so many did not see the wisdom in the this path of study, private philanthropy made it possible for our investigators to pursue leads. The Kimmel Scholars program, the Clayton Fund, the Hodson Trust, the Commonwealth Foundation, Ludwig Cancer Research, Stand Up To Cancer, and so many more provided the critical support that allowed this research to happen
Great ideas inspire others, and now everyone working on cancer is thinking about genetics, epigenetics, and immunology, but I would argue that no place has the concentration of talent and ardor as the Kimmel Cancer Center. Cancer science becoming cancer medicine is the core value that influences everything we do here. To bridge the laboratory and the bedside, our investigators and clinicians have cleverly developed innovative ways to analyze and quantify these molecular contributors to cancer development and growth and developed precise platforms to transfer their discoveries to patient care. This is where we excel and what sets us apart.
The opportunity to expand our collaborations and partnerships has never been greater. Discoveries in cancer genetics, epigenetics, and immunology have truly launched an industry. Our scientists have identified the molecular targets and ways to interfere with these targets to impede cancer. Pharmaceutical companies have worked with our experts to develop drugs that hit these targets, and funders like Stand Up To Cancer are helping move these new therapies to patients. All three components were necessary to get us where we are today, creating the model for how 21st century cancer science and medicine is done.
William G. Nelson, M.D., Ph.D
Marion I. Knott Professor and Director
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Articles in this Issue
- Headline Makers - Overview
- A Safer Way to Treat Pediatric Brain Cancers
- For Cervical Lesions, Tissue Exam Beats Conventional Blood Tests
- Blood Cells Transformed to Repair Damaged Retina
- Personalized Chemotherapy
- 3D Scans Show whether Treatment is Working
- Alcohol Metabolite Could Increase Cancer Risk in Some People
- Acupuncture, Real or Simulated, Eases Hot Flashes
- New Leukemia Findings
- HPV Oral Cancers and Risk of Infection for Couples
- Molecular Marker of Cancer Drug Response
- Chronic Inflammation Connected to Prostate Cancer
- Fat Versus Brain Cancer
- DNA Damaging Toxins In Food
- Cancer Patients Who Quit Smoking Live Longer
- New Immune Therapy Shows Promise Against Melanoma
- Breathe Easier and Fight Cancer
- Cost-Cutting and Excellent Care Not Mutuallly Exclusive
- The Key to Safe Bone Marrow Transplants Revealed
- Gene-Based Blood Tests Detect Advanced and Early Cancers